Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 905812 | Other Grant/Funding Number | American Heart Association |
Not provided
Not provided
Not provided
Funding was inconsistent and the Post-Doc left before the project ended
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| American Heart Association | OTHER |
Not provided
Not provided
Not provided
Not provided
Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that has shown promise in improving cardiovascular outcomes in similar populations. Thus the purpose of this study is to test if MitoQ can improve cardiovascular health in COPD.
In this study, a mitochondria-specific antioxidant will be compared to a placebo. Participants will be assigned randomly to receive either the antioxidant or the placebo for 6 weeks. A comprehensive assessment of cardiovascular health will be conducted before and after the administration of the supplement.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MitoQ | Experimental | Participants will take 1 pill each day for 6 weeks |
|
| Placebo | Placebo Comparator | Participants will take 1 pill each day for 6 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MitoQ | Drug | MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change in vascular function | Flow-mediated dilation will be used to measure vasodilation in the brachial artery | Baseline and 6 weeks |
| Change in Skeletal Muscle Oxygenation | Near-infrared spectroscopy will be used to measure leg muscle oxygenation | Baseline and 6 weeks |
| Change in oxidative stress | Blood draws will be taken to measure oxidative stress markers in the blood through electron paramagnetic resonance | Baseline and 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in arterial stiffness | Pulse wave velocity will be used to measure arterial stiffness. | Baseline and 6 weeks |
| Change in microvascular function | Microvascular function will be assessed using laser dopler imaging |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Paula Rodriguez-Miguelez, PhD | Virginia Commonwealth University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Virginia Commonwealth University | Richmond | Virginia | 23298 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| C429014 | mitoquinone |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Other |
A look-alike inactive substance, a "sugar pill" |
|
| Baseline and 6 weeks |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |